The OPTIMAL Randomized Controlled Trial (OPTIMAL)
OPtimizaTIon of Left MAin PCI With IntravascuLar Ultrasound. The OPTIMAL Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ernest Spitzer, MD
- Phone Number: 0031102062828
- Email: E.Spitzer@ECRI-Trials.com
Study Contact Backup
- Name: Anita van der Wal
- Phone Number: 0031102062828
Study Locations
-
-
-
Bergamo, Italy
- Asst Papa Giovanni Xxiii
-
Ferrara, Italy
- A.O.U. di Ferrara
-
Florence, Italy
- Interventistica Cardiologica Strutturale
-
Milan, Italy
- ASST Niguarda
-
Milan, Italy
- Policlinco San Donato
-
Milan, Italy
- Sant'Ambrogio Clinical Institute
-
Rome, Italy
- Policlinico Umberto I
-
Verona, Italy
- AOUI Verona
-
-
-
-
-
A Coruña, Spain
- Hospital Universitario de A Coruña
-
Barcelona, Spain
- Hospital de Bellvitge
-
Barcelona, Spain
- Hospital Vall D´Hebron
-
Córdoba, Spain
- Hospital Reina Sofía
-
Gijón, Spain
- Hospital de Cabueñes
-
Madrid, Spain
- Hospital Clinico San Carlos
-
Murcia, Spain
- Hospital Clinico Universiatrio V. Arrixaca
-
Santander, Spain
- Hospital Universitario Marqués de Valdecilla
-
Vigo, Spain
- Hospital Alvaro Cunqueiro
-
Zaragoza, Spain
- Hospital Clinico Lozano Blesa
-
-
-
-
-
Belfast, United Kingdom
- Royal Victoria Hospital
-
Bournemouth, United Kingdom
- Royal Bournemouth Hospital
-
Brighton, United Kingdom
- Royal Sussex Country Hospital
-
Bristol, United Kingdom
- Bristol Royal Infirmary
-
Cardiff, United Kingdom
- University Hospital of Wales
-
Clydebank, United Kingdom
- Golden Jubilee National Hospital
-
Leeds, United Kingdom
- Leeds General Infirmary
-
London, United Kingdom
- St Bartholomew's Hospital
-
Newcastle upon Tyne, United Kingdom
- The Freeman Hospital
-
Oxford, United Kingdom
- John Radcliffe Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient must be ≥ 18 years of age;
- De novo lesion in an unprotected left main coronary artery (ULMCA; ostial, shaft or distal) OR ostial left anterior descending artery (LAD) or ostial circumflex (LCX), both compatible with one Medina class of LM disease; or ostial intermediate branch disease;
- PCI is considered appropriate and feasible by the treating interventionalist;
- Silent ischemia, stable angina, unstable angina, or non-ST segment elevation MI;
- Able to understand and provide informed consent and comply with all study procedures, including follow-up for at least 2 years.
Note: A patient with a prior CABG with no patent bypass on the left main coronary artery (LMCA) can be included.
Exclusion Criteria:
- Patient is a woman who is pregnant or nursing;
- Female patient of childbearing potential, i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause);
- IVUS is strictly required for pre-PCI lesion severity assessment
- ST-elevation myocardial infarction, cardiogenic shock;
- Previous history of CABG with patent graft to the LAD and/or patent graft to the LCX;
- Prior PCI of the LM, ostial LAD or ostial LCX at any time prior to enrollment;
- Prior PCI of any other (i.e. non-LM, non-ostial-LAD and non-ostial-LCX) coronary artery lesions within 30 days prior to enrollment;
- Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 6 months in stable patients and 1 year in ACS patients;
- Known contraindication or hypersensitivity to everolimus, platinum-chromium, or to anticoagulants.
- Patients requiring additional surgery (cardiac or non-cardiac) within 3 months post-enrollment;
- Non-cardiac co-morbidities with a life expectancy less than 2 years;
- Currently participating in another trial that is not yet at its primary endpoint. The patient is not allowed to participate in another investigational device or drug study for at least 12 months after enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IVUS guided PCI
Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
|
Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
|
|
Active Comparator: Angiography-guided PCI
Qualitative or quantitative angiography will be used to determine lesion characteristics
|
Qualitative or quantitative angiography will be used to determine lesion characteristics
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient-oriented Composite Endpoint (POCE)
Time Frame: 2-5 years follow up
|
Patient-oriented Composite Endpoint (PoCE): composite of all-cause death, any stroke, any myocardial infarction (MI)*, any clinically indicated revascularization at longest follow-up.
|
2-5 years follow up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device-oriented Composite Endpoint (DoCE)
Time Frame: 2-5 years follow up
|
Device-oriented Composite Endpoint (DoCE) defined as the composite of: Cardiovascular death, target vessel MI, clinically indicated repeat revascularization of the target lesion at longest follow-up
|
2-5 years follow up
|
|
Vessel-oriented Composite Endpoint (VoCE)
Time Frame: 2-5 years follow up
|
Vessel-oriented Composite Endpoint (VoCE) defined as the composite of: left main related cardiac death, target vessel MI, clinically indicated -repeat revascularization of the left main vessels at longest follow-up.
|
2-5 years follow up
|
|
Patient-oriented Composite Endpoint (POCE)
Time Frame: 2 year follow up
|
Patient-oriented Composite Endpoint (PoCE): composite of all-cause death, any stroke, any myocardial infarction (MI)*, any clinically indicated revascularization at 2 years follow-up.
|
2 year follow up
|
|
All individual components of PoCE at all time points.
Time Frame: 2-5 years follow-up
|
All individual components of PoCE at all time points.
|
2-5 years follow-up
|
|
All individual components of DoCE at all time points.
Time Frame: 2-5 years follow-up
|
All individual components of DoCE at all time points.
|
2-5 years follow-up
|
|
Definite and probable stent thrombosis
Time Frame: 2-5 years follow-up
|
Definite and probable stent thrombosis according to ARC definition
|
2-5 years follow-up
|
|
Hospitalization for heart failure
Time Frame: 2-5 years follow-up
|
Investigator reported hospitalization for heart failure
|
2-5 years follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Adrian Banning, Prof, Oxford University Hospitals NHS Trust
- Principal Investigator: Luca Testa, Dr., Policlinco San Donato
Publications and helpful links
General Publications
- De Maria GL, Testa L, de la Torre Hernandez JM, Terentes-Printzios D, Emfietzoglou M, Scarsini R, Bedogni F, Spitzer E, Banning A. A multi-center, international, randomized, 2-year, parallel-group study to assess the superiority of IVUS-guided PCI versus qualitative angio-guided PCI in unprotected left main coronary artery (ULMCA) disease: Study protocol for OPTIMAL trial. PLoS One. 2022 Jan 7;17(1):e0260770. doi: 10.1371/journal.pone.0260770. eCollection 2022.
- Testa L, De la Torre Hernandez JM, De Maria GL, Jones DA, Pinon-Esteban P, Campo G, Garcia Del Blanco B, Pan M, Garcia-Camarero T, Sardella G, O'Kane P, Greenwood JP, Ribichini FL, Pescetelli I, Ielasi A, Lozano I, Cockburn J, Oreglia JA, Zaman AG, Bedogni F, Lindeboom W, Tijssen JGP, Spitzer E, Banning AP; OPTIMAL Investigators. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMoa2600440. Online ahead of print.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ECRI-013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.